Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[89Zr]DFO-starPEG
- Development stage
- Phase 1
- Lead developer
- ProLynx
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**[89Zr]DFO-starPEG** is a novel diagnostic radiopharmaceutical developed for imaging purposes using positron emission tomography (PET). It consists of the radionuclide **zirconium-89 ([89Zr])** complexed by **desferrioxamine (DFO)**, which is conjugated to a multi-armed polyethylene glycol (starPEG) molecule. The tracer is designed to visualize **enhanced permeability and retention (EPR)-mediated uptake** in solid tumors. Its primary indication is to act as an imaging surrogate, specifically for mapping EPR effects in neoplasms before administration of EPR-based nanomedicines. Its mechanism is based on the passive accumulation in tumors via the EPR effect, allowing for whole-body PET imaging and dosimetric assessment in patients with malignant solid neoplasms and soft tissue lesions[1][5][7][8]. The agent’s biodistribution, safety, and pharmacokinetics are being characterized in first-in-human phase 1 clinical studies.
- Other names
- [89Zr]DFO-starPEGPET [89Zr]DFO-starPEG89-zr-dfo-star polyethylene glycol
Beyond the preview
Go deeper on [89Zr]DFO-starPEG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [89Zr]DFO-starPEG.